Trimbow

Negara: Uni Eropa

Bahasa: Inggris

Sumber: EMA (European Medicines Agency)

Beli Sekarang

Selebaran informasi Selebaran informasi (PIL)
01-04-2022
Karakteristik produk Karakteristik produk (SPC)
01-04-2022

Bahan aktif:

Beclometasone dipropionate, formoterol fumarate dihydrate, Glycopyrronium bromide

Tersedia dari:

Chiesi Farmaceutici S.p.A.

Kode ATC:

R03AL09

INN (Nama Internasional):

beclometasone, formoterol, glycopyrronium bromide

Kelompok Terapi:

Drugs for obstructive airway diseases,

Area terapi:

Pulmonary Disease, Chronic Obstructive

Indikasi Terapi:

Maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.COPDMaintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or a combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.1).AsthmaMaintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year. 

Ringkasan produk:

Revision: 7

Status otorisasi:

Authorised

Tanggal Otorisasi:

2017-07-17

Selebaran informasi

                                95
B. PACKAGE LEAFLET
96
PACKAGE LEAFLET: INFORMATION FOR THE USER
TRIMBOW 87 MICROGRAMS/5 MICROGRAMS/9 MICROGRAMS PRESSURISED
INHALATION, SOLUTION
beclometasone dipropionate/formoterol fumarate
dihydrate/glycopyrronium
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Trimbow is and what it is used for
2.
What you need to know before you use Trimbow
3.
How to use Trimbow
4.
Possible side effects
5.
How to store Trimbow
6.
Contents of the pack and other information
1.
WHAT TRIMBOW IS AND WHAT IT IS USED FOR
Trimbow is a medicine to help breathing that contains the three active
substances:
•
beclometasone dipropionate,
•
formoterol fumarate dihydrate and
•
glycopyrronium.
Beclometasone dipropionate belongs to a group of medicines called
corticosteroids which act to
reduce the swelling and irritation in your lungs.
Formoterol and glycopyrronium are medicines called long-acting
bronchodilators. They act in
different ways to relax the muscles in your airways, helping to open
the airways wider and allowing
you to breathe more easily.
Regular treatment with these three active substances helps to relieve
and prevent symptoms such as
shortness of breath, wheezing and cough in adult patients with
obstructive lung disease.
Trimbow is used for the regular treatment of
•
chronic obstructive pulmonary disease (COPD) in adults
•
asthma in adults.
Trimbow can reduce exacerbations (flare-ups) of COPD and asthma
symptoms.
COPD is a serious long-term disease in which the airways become
blocked and air sacs 
                                
                                Baca dokumen lengkapnya
                                
                            

Karakteristik produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Trimbow 87 micrograms/5 micrograms/9 micrograms pressurised
inhalation, solution
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each delivered dose (the dose leaving the mouthpiece) contains 87
micrograms of beclometasone
dipropionate, 5 micrograms of formoterol fumarate dihydrate and 9
micrograms of glycopyrronium (as
11 micrograms glycopyrronium bromide).
Each metered dose (the dose leaving the valve) contains 100 micrograms
of beclometasone
dipropionate, 6 micrograms of formoterol fumarate dihydrate and 10
micrograms of glycopyrronium
(as 12.5 micrograms glycopyrronium bromide).
Excipient with known effect:
Trimbow contains 8.856 mg ethanol per actuation.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Pressurised inhalation, solution (pressurised inhalation)
Colourless to yellowish liquid solution.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Chronic obstructive pulmonary disease (COPD)
Maintenance treatment in adult patients with moderate to severe COPD
who are not adequately treated
by a combination of an inhaled corticosteroid and a long-acting
beta2-agonist or a combination of a
long-acting beta2-agonist and a long-acting muscarinic antagonist (for
effects on symptoms control
and prevention of exacerbations see section 5.1).
Asthma
Maintenance treatment of asthma, in adults not adequately controlled
with a maintenance combination
of a long-acting beta2-agonist and medium dose of inhaled
corticosteroid, and who experienced one or
more asthma exacerbations in the previous year.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
The recommended dose is two inhalations twice daily.
The maximum dose is two inhalations twice daily.
Patients should be advised to take Trimbow every day even when
asymptomatic.
If symptoms arise in the period between doses, an inhaled,
short-acting beta2-agonist should be used
for immediate relief.
3
_Asthma _
When choosing the starting dose strength of Trimbow (87/5/9 micro
                                
                                Baca dokumen lengkapnya
                                
                            

Dokumen dalam bahasa lain

Selebaran informasi Selebaran informasi Bulgar 01-04-2022
Karakteristik produk Karakteristik produk Bulgar 01-04-2022
Laporan Penilaian publik Laporan Penilaian publik Bulgar 26-02-2021
Selebaran informasi Selebaran informasi Spanyol 01-04-2022
Karakteristik produk Karakteristik produk Spanyol 01-04-2022
Laporan Penilaian publik Laporan Penilaian publik Spanyol 26-02-2021
Selebaran informasi Selebaran informasi Cheska 01-04-2022
Karakteristik produk Karakteristik produk Cheska 01-04-2022
Laporan Penilaian publik Laporan Penilaian publik Cheska 26-02-2021
Selebaran informasi Selebaran informasi Dansk 01-04-2022
Karakteristik produk Karakteristik produk Dansk 01-04-2022
Laporan Penilaian publik Laporan Penilaian publik Dansk 26-02-2021
Selebaran informasi Selebaran informasi Jerman 01-04-2022
Karakteristik produk Karakteristik produk Jerman 01-04-2022
Laporan Penilaian publik Laporan Penilaian publik Jerman 26-02-2021
Selebaran informasi Selebaran informasi Esti 01-04-2022
Karakteristik produk Karakteristik produk Esti 01-04-2022
Laporan Penilaian publik Laporan Penilaian publik Esti 26-02-2021
Selebaran informasi Selebaran informasi Yunani 01-04-2022
Karakteristik produk Karakteristik produk Yunani 01-04-2022
Laporan Penilaian publik Laporan Penilaian publik Yunani 26-02-2021
Selebaran informasi Selebaran informasi Prancis 01-04-2022
Karakteristik produk Karakteristik produk Prancis 01-04-2022
Laporan Penilaian publik Laporan Penilaian publik Prancis 26-02-2021
Selebaran informasi Selebaran informasi Italia 01-04-2022
Karakteristik produk Karakteristik produk Italia 01-04-2022
Laporan Penilaian publik Laporan Penilaian publik Italia 26-02-2021
Selebaran informasi Selebaran informasi Latvi 01-04-2022
Karakteristik produk Karakteristik produk Latvi 01-04-2022
Laporan Penilaian publik Laporan Penilaian publik Latvi 26-02-2021
Selebaran informasi Selebaran informasi Lituavi 01-04-2022
Karakteristik produk Karakteristik produk Lituavi 01-04-2022
Laporan Penilaian publik Laporan Penilaian publik Lituavi 26-02-2021
Selebaran informasi Selebaran informasi Hungaria 01-04-2022
Karakteristik produk Karakteristik produk Hungaria 01-04-2022
Laporan Penilaian publik Laporan Penilaian publik Hungaria 26-02-2021
Selebaran informasi Selebaran informasi Malta 01-04-2022
Karakteristik produk Karakteristik produk Malta 01-04-2022
Laporan Penilaian publik Laporan Penilaian publik Malta 26-02-2021
Selebaran informasi Selebaran informasi Belanda 01-04-2022
Karakteristik produk Karakteristik produk Belanda 01-04-2022
Laporan Penilaian publik Laporan Penilaian publik Belanda 26-02-2021
Selebaran informasi Selebaran informasi Polski 01-04-2022
Karakteristik produk Karakteristik produk Polski 01-04-2022
Laporan Penilaian publik Laporan Penilaian publik Polski 26-02-2021
Selebaran informasi Selebaran informasi Portugis 01-04-2022
Karakteristik produk Karakteristik produk Portugis 01-04-2022
Laporan Penilaian publik Laporan Penilaian publik Portugis 26-02-2021
Selebaran informasi Selebaran informasi Rumania 01-04-2022
Karakteristik produk Karakteristik produk Rumania 01-04-2022
Laporan Penilaian publik Laporan Penilaian publik Rumania 26-02-2021
Selebaran informasi Selebaran informasi Slovak 01-04-2022
Karakteristik produk Karakteristik produk Slovak 01-04-2022
Laporan Penilaian publik Laporan Penilaian publik Slovak 26-02-2021
Selebaran informasi Selebaran informasi Sloven 01-04-2022
Karakteristik produk Karakteristik produk Sloven 01-04-2022
Laporan Penilaian publik Laporan Penilaian publik Sloven 26-02-2021
Selebaran informasi Selebaran informasi Suomi 01-04-2022
Karakteristik produk Karakteristik produk Suomi 01-04-2022
Laporan Penilaian publik Laporan Penilaian publik Suomi 26-02-2021
Selebaran informasi Selebaran informasi Swedia 01-04-2022
Karakteristik produk Karakteristik produk Swedia 01-04-2022
Laporan Penilaian publik Laporan Penilaian publik Swedia 26-02-2021
Selebaran informasi Selebaran informasi Norwegia 01-04-2022
Karakteristik produk Karakteristik produk Norwegia 01-04-2022
Selebaran informasi Selebaran informasi Islandia 01-04-2022
Karakteristik produk Karakteristik produk Islandia 01-04-2022
Selebaran informasi Selebaran informasi Kroasia 01-04-2022
Karakteristik produk Karakteristik produk Kroasia 01-04-2022
Laporan Penilaian publik Laporan Penilaian publik Kroasia 26-02-2021

Lihat riwayat dokumen